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Abstract
Anxiety affects approximately three to seven percent of the United States population, and nearly
50% of the diagnosed patients fail to respond to first-line treatment regimens (Boland, Duffy, &
Meyer 2018). Traditional first-line treatments include medication therapy, cognitive behavioral
therapy (CBT), or the combination of both. With such a high initial failure rate, recent studies
indicate promising results in managing anxiety with pharmacogenomic testing.
Pharmacogenomic testing is allowing providers to prescribe medication based on individual
genetic makeup, focusing on how each patient metabolizes certain medications. The purpose of
this literature review was to determine if first-line methods or pharmacogenomic testing provide
patients with more prompt symptom relief. Through a review of several electronic databases and
articles, pharmacogenomic testing is yielding promising results in symptom relief, decreasing
healthcare costs, and increasing healthcare efficacy. Not only is pharmacogenomic testing
promising for anxiety management, it also gives insight to several other medication classes. With
this information, pharmacogenomic testing may soon be a screening tool in future medicine.
Keywords: anxiety, pharmacogenomic testing, anxiety management, first-line anxiety
treatment
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Introduction
According to DynaMed Plus (2018), “Anxiety is characterized by chronic, unfocused,
excessive worry and stress associated with clinically significant distress and functional
impairment, often accompanied by insomnia, restlessness, muscle tension, and concentration
problems.” Anxiety affects approximately three to seven percent of the United States population,
and nearly 50% of those affected fail to respond to first-line treatment regimens, such as
medication and/or therapy (Boland et al., 2018). Failed treatment can be influenced by
environment exposures, nutrition, co-morbidities, severity of disease, and medication
interactions (Lee, 2018). The purpose of this review is to determine if anxiety management
should be based on pharmacogenomic testing or if providers should continue to use first-line
methods.
Statement of the Problem
Underdiagnosis of anxiety is quite common, with an average patient seeing 10 healthcare
professionals before a definitive diagnosis is made, which can lead to increased health care costs
in comparison to other disorders (Lee, 2018). First-line treatment for anxiety includes selective
serotonin reuptake inhibitor (SSRI) medications, cognitive behavioral therapy (CBT), or the
combination of both. According to Genome Wide Association Studies (GWAS), genetic
variation alone accounts for 42% of varied first-line therapy response (Boland et al., 2018). Due
to a person’s genetic make-up, patients are not being prescribed the most effective medication
given their deoxyribonucleic acid (DNA). With such a high initial failure rate, pharmacogenomic
testing has become an area of research. With this research, it is thought patients can experience
symptom relief upon initial treatment, prevent future relapse, reduce healthcare costs, and
improve overall healthcare efficacy.
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Research Questions
In treating anxiety, do those who elect to have pharmacogenomic testing versus those
who are treated based on first-line treatments have better symptom management?
In managing anxiety, would patients who respond to pharmacogenetic testing have
decreased healthcare costs and improve overall healthcare efficacy in comparison to those who
trial several medications?
Review of Literature
In researching anxiety, ClinicalKey, the Cochrane Library, DynaMed Plus, and PubMed
were utilized to find high-quality reviews of randomized controlled trials and cohort studies.
Some articles were used for background information on the pathophysiology of anxiety and to
provide additional information regarding pharmacogenomic testing. Several articles were
eliminated due to lack of evidence and lack of focus on anxiety. Most articles focus on the
combination of depression and anxiety, since the two typically coexist and are treated with the
same drug class. Keywords searched included: anxiety, generalized anxiety disorder,
pathophysiology of anxiety, anxiety management, first-line treatment for anxiety,
pharmacogenomic testing in anxiety, pharmacogenetic testing in anxiety, anxiety biomarkers,
cost effectiveness of pharmacogenomic testing, and cost benefits of pharmacogenomic testing in
managing anxiety. All studies included were published in a peer-reviewed sourced within the last
13 years, and all were written in the English language.
Pathophysiology of Anxiety
According to Diagnostic and Statistical Manual of Mental Disorders, 5 th Edition (DSMV) criteria, individuals must present with a consecutive six month or greater history of
disproportionally high levels of anxiety, fear, or worry for most days, with disruption of daily
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living being the most defining characteristic (Lee, 2018). Worry must be accompanied by at least
three somatic symptoms in adults and at least one in children. Somatic symptoms can include,
but are not limited to, restlessness, irritability, sleep disturbance, lack of concentration, muscle
tension, or fatigue. Although somatic symptoms must be present, patients typically report
diaphoresis, headache, and/or trembling (Lee, 2018).
Generalized anxiety disorder (GAD) is the most common type of anxiety, but anxiety
offers several different subtypes including: obsessive compulsive disorder (OCD), post-traumatic
stress disorder (PTSD), panic disorder, and phobias all in which are marked by irrational,
involuntary thoughts (Lee, 2018). GAD is likely to be present in combination with another
psychiatric condition and/or medical problem(s). It is not uncommon for patients to present with
both anxiety and depression; with one typically causing the other. When the two coexist, primary
treatment focuses on depression. Alcohol and drug abuse are common in patients with anxiety;
30% of anxiety patients report alcohol use to mask their symptoms, while 17% admit to drug use
(Lee, 2018).
Pathophysiology of anxiety remains multifactorial and not fully understood. Studies have
focused research on different body structures and systems to help better understand pathogenesis,
mainly focusing on the amygdala (Lee, 2018). According to Lee (2018), “The amygdala is a
small structure deep inside the brain that communicates with the autonomic nervous system to
relay perceived danger to other centers of the brain which, in turn, readies the body to respond to
perceived danger” (p. 46). The memory of these dangers is engrained in the amygdala, creating a
pathophysiologic phenomenon perhaps leading to the pathogenesis of GAD. Current research is
looking into the correlation of early childhood exposure to stress and later development of GAD
(Lee, 2018).
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According to Zun and Nordstrom (2018), the serotonin and noradrenergic systems are
common pathways implicated in anxiety. With low serotonin system activity and elevated
noradrenergic system activity, SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs)
are frequently used as treatment in a patient with anxiety. In additional research, the
effectiveness of benzodiazepine use in anxiety management has led to the study of the gammaaminobutyric acid (GABA) system. “GABA is the principal inhibitory neurotransmitter in the
central nervous system, and benzodiazepines act on the GABA A receptors” (Zun and
Nordstrom, 2018, p.1353).
Studies have also focused on the role that corticosteroids play in managing anxiety.
While under stress, steroids are thought to induce chemical changes in select neurons that
strengthen or weaken certain neural pathways that affect behavior (Zun and Nordstrom, 2018).
Low cortisol levels and increased norepinephrine and epinephrine levels are noted in patients
with PTSD (Zun and Nordstrom, 2018).
Genetic research suggests that inherited genes may play a role in anxiety, but again the
pathogenesis is not fully understood. According to Lee (2018), studies report, “Genetic
concordance with certain genetic loci that produce functional serotonin polymorphisms” (p. 47).
Several anxiety subtypes share genetic and environmental risk factors in biologically predisposed
individuals (Zun and Nordstrom, 2018).
Pharmacogenomic testing has been an area of recent research, not only for anxiety but
several other health conditions. This testing provides information on genotypes and predicted
phenotypes, allowing providers to select medications on each individual genetic make-up.
Research for anxiety management is focusing on Cytochrome P450 (CYP450) gene, which is
responsible for oxidation of antidepressant medications (Boland et al., 2018), along with
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cytochrome P450 2D6 (CYP2D6) and cytochrome P450 2C19 (CYP2C19), which are enzymes
responsible for the metabolism of SSRIs (Drozda, Muller & Bishop, 2015). Race also plays an
important role in selecting medication. Research by (Drozda et al., 2015) suggests CYP2D6
variation is most commonly found in Caucasians, in comparison to African Americans or Asians.
Those with variations in CYP2D6 and CYP2C19 genes are in that population that are failing
first-line treatment because of how their bodies metabolize SSRI medications (Drozda et al.,
2015). Genetic testing results can be useful in starting target dosing and can potentially warn
patients of drug interactions and/or side effects. Since anxiety is thought to have a genetic link,
along with cytochrome variation having an inherited trait, pharmacogenomic testing may be
beneficial in subsequent family members diagnosed with anxiety.
First-line Treatment for Anxiety
Current first-line treatment for GAD includes SSRI medication, CBT, or the combination
of both. Many individuals who seek treatment for GAD decline to receive combination therapy
(Crits-Christoph et al., 2012). The authors reported an 18-month study consisting of three phases:
phase one was a six-month open-label venlafaxine flexible-dose treatment phase (75mg225mg/day), phase two and three were each six-month randomized, double-blinded, placebocontrolled relapse phase (Crits-Christoph et al., 2012). While three phases were studied, only
phase one was reported which compared venlafaxine extended release (XR) versus venlafaxine
XR in combination with CBT to manage GAD. Eligible patients were over the age of 18, met the
Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for GAD,
scored ≥ four on the Clinical Global severity scale, scored ≥ 20 on the Hamilton Anxiety Rating
Scale (HAM-A), and were recruited through community outreach, mailings, media advertising,
and referrals from primary care physicians (Crits-Christoph et al., 2012).
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Patients were randomly selected to either receive 12 sessions of CBT (n=77) or not to
receive CBT (n=40); of the selected population, only 33% (n=26) accepted CBT (Crits-Christoph
et al., 2012). Patients in both treatment groups showed improvement, with 65% of patients in the
combined treatment group meeting criteria for HAM-A clinical response by the end of the study
compared to 71% receiving only venlafaxine XR group (p=0.63) (Crits-Christoph et al., 2012).
There was no evidence of additional benefit of combined venlafaxine and CBT, but the
results may have been skewed by the effectiveness of venlafaxine XR (Crits-Christoph et al.,
2012). The authors note the lack of interest in combination therapy may have been influenced by
the study setting. Primary care and psychopharmacology clinics recruited patients only after they
agreed to participate in a medication trial. Those who elected to receive CBT frequently reported
to their therapist the positive impact of venlafaxine XR (Crits-Christoph et al., 2012).
Coordinated Anxiety Learning and Management (CALM) offers CBT, medication, or a
combination of both, and is a treatment model designed to treat anxiety disorders in a primary
care setting (Joesch et al., 2013). This study discusses cost and benefits of CALM versus primary
methods. In total 1,062 patients, from 17 different clinics and four different cities were part of
this randomized trial. Of the 1,062 patients, 1,004 were English or Spanish-speaking aged 18-75
years, and had a diagnosis of panic, GAD, social anxiety, and/or PTSD with or without major
depression. Patients were either part of the CALM trial group or part of the usual care (UC)
group. Over an 18-month period, an average of 57.1% of CALM participants experienced more
anxiety free days, had $245 of additional medical expenses due to additional primary care visits
in comparison to the UC group (Joesch et al., 2013).
Several study limitations were noted by the authors. Cost and benefits were based on the
first 18 months, studies of collaborative care of anxiety and depression benefits and cost may
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extend beyond this 18-month period (Joesch et al., 2013). The cost estimates were based on selfreporting, therefore results of the CALM net benefit may be biased. The cost estimates do not
cover medical procedures or other non-psychiatric medications; CALM participants underwent
fewer procedures. It was difficult for the authors to distinguish between costs of primary care and
Anxiety Clinical Specialist (ASC). ASC visits are typically cheaper than primary care visits.
Only 70% of the initial participants were calculated into the results. Without 100% of patients
reporting, the missing 30% could have possibly changed the results of this study (Joesch et al.,
2013).
Pharmacogenomic Testing in Managing Anxiety
Boland et al., (2018) acknowledge anxiety can be influenced by: environmental
exposures, nutrition, co-morbidities, disease severity, and medication interactions. 50% of
patients diagnosed with GAD fail to respond to first-line treatment options, and of this 50%, half
of this population is failing anxiety treatment due to genetic variation (Boland et al., 2018).
Research is focusing on CYP450 gene, which is responsible for oxidation of antidepressant
medications. Although the Food and Drug Administration (FDA) has approved 19 different
antidepressant medications in genetic testing, inconsistent evidence incorporated into treatment
guidelines has prevented this from becoming standard of care in a clinical setting. This study was
conducted on 468 patients who had depression (n=297) or GAD (n=171), but only 86 (18.4%) of
patients completed all the appropriate documents, greatly reducing the study population. The
mean age of the population group was 42, with no preference to gender, age, or race (Boland, et
al., 2018).
Initial medication regimens included: 43.8% of patients were prescribed SSRIs, 22%
SNRIs, 19.4% other, and 8.97% folate derivatives (Boland et al., 2018). After receiving genetic
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results, 83.6% (391) patients were switched to a different medication; while 16.5% (77) were not
(Boland et al., 2018). SSRI drug class was the most frequently discontinued medication (19%) at
one month and (an additional 10.8%) at three months; these patients had a serotonin transporter
gene known as, solute carrier family 6 member 4 (SLC6A4) (Boland et al., 2018). Thus, making
them at greater risk for SSRI intolerance leading to a poor medication response (Boland et al.,
2018). At a three-month follow up, 50.6% of patients remained on medications from the genetic
testing results (Boland et al., 2018). The rate of SSRI use decreased by 17.6%, SNRI increased
by 25.2%, and whole folate derivatives increased by 431%, especially in those with
methylenetetrahydrofolate reductase (MTHFR) risk genotype which can cause high levels of
homocysteine and low levels of folate (Boland et al., 2018).
Those with SLC6A4 and MTHFR genotype benefit from pharmacogenomic testing, by
eliminating drugs that will not produce effective metabolism (Boland et al., 2018). Genetic
analysis is limited in this study as both depression and anxiety are both observed, and not just
anxiety. The overlap of the two conditions can make diagnosis at times indistinguishable. The
authors of this study emphasize the lack in report of genetic inheritance and how this could
potentially play a role in treatment.
Bradly et al., (2018) estimates over 40 million of United States adults over the age of 18
are affected by anxiety. The disease is linked to $42 billion in annual healthcare costs (Bradley et
al., 2018). Only one-third of those suffering from anxiety receive treatment, and of this
population only 60% respond to treatment (Bradley et al., 2018). It is suggested that anxiety is
difficult to treat due to dual diagnosis of depression. This study focused on an age range of 1987, with initial selection of 764 patients, but 79 of those were excluded resulting in 685 patients
(Bradley et al., 2018). The mean age was 48 with 73% female and 27% male (Bradley et al.,
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2018). The DSM-V criteria was used to diagnose a patient with depression and/or anxiety. A
total of 579 patients completed the study (297 experimental, 282 control). (Bradley et al., 2018).
This study compared pharmacogenetic-guided treatment (experimental group) in
comparison to standard of care treatment (control group) (Bradley et al., 2018). Patients were
measured for depression and anxiety at baseline, four, eight, and 12 weeks, and were classified
as having moderate to severe anxiety based on HAM-A scores of ≥ 18 (Bradley et al., 2018).
Using NeuroIdgenetix® guided treatment, patients classified to have moderate to severe anxiety
showed a reduction in anxiety symptoms. HAM-A scores at four, eight, 12-week appointments
also indicated a 39%, 47% and 54% percentage reduction for those who received
pharmacogenomic testing versus the control group 26%, 35%, and 42% (p=0.004, 0.02, 0.02)
(Bradley et al, 2018).
The authors stressed the significance in how a test is interpreted and implemented by a
provider. In this study, 81% of subjects in the experiment group were changed to a different
medication at their two-week follow up; while only 64% of subjects in the control were changed
(p<0.0001) (Bradley et al., 2018). Thus, indicates that NeuroIdgenetix® results provided
physicians with clear concise information to justify a medication change (Bradley, et al., 2018).
This trial had some limitations. It looked at three different patient populations: anxiety,
depression, and a combination of depression and anxiety, which sometimes can be difficult to
diagnose the three different combinations. Critically ill patients were excluded from the trial;
therefore, it is unknown the response that population would have from pharmacogenomic testing.
Only those with moderate to severe depression were part of the patient population; those with
mild depression were excluded.
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Drozda et al. (2015) acknowledge advances in pharmacogenetic testing are allowing
providers to integrate personalized medicine into their practice. Many tests are available, but
research suggests providers become familiar with the interpretation of the result because many
different genetic variants are taken into consideration by each developer. Genetic information is
useful in starting target doses and drug interactions in managing psychiatric and neurological
conditions. CYP2D6 and CYP2C19 are two enzymes responsible for the metabolism of SSRIs,
which are used to treat anxiety. At the time of this study, 110 different medications were listed in
pharmacogenomic biomarker product labeling. Of the 32 neuropsychiatric medications, 27
(84%) have CYP2D6 metabolizers listed, and three (9%) list CYP2C19 metabolizers, the other
three (9%) list as others (Drozda et al., 2015). Only 10 of the 32 listed in this trial provide
information regarding dosing, precautions, or warnings (Drozda et al., 2015).
At the time of this review, the authors pointed out further research has suggested benefits
when the test results are applied to clinical scenarios. However, more studies need to be
concluded on race-ethnicity gene variants. For example, CYP2D6 is most commonly seen in
Caucasians in comparison to Asians and African Americans. Thus, with such variation amongst
the population, providers must select the appropriate test selection based on one’s ancestry
(Drozda et al., 2015).
Maron and Nutt (2017) viewed data on neuroimaging, genetic, and neurochemical
measurement of GAD to guide treatment based on pharmacogenomic biomarkers. Little
advancement has been made to effectively treat GAD. Since there is an overlap of GAD and
depression, anxiety disorders are at times difficult to diagnose. This review indicates differences
in biology of GAD and depression to help distinguish the two diseases. With such differences,
advancements in improving diagnosis and treatment will be better understood using genetic
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biomarkers. In combination of several studies, there are not clear and consistent results for
biomarkers to be translated into clinical practice. Thus, the review and authors conclude further
research is needed to distinguish the overlap of many psychiatric conditions (Maron and Nutt,
2017).
Gottschalk and Domschke (2017) researched the genetic aspect of familial and twin
inheritability of GAD to include: gene-environment factors, childhood trauma, environmental
adversity, and stressful life situations in relations to selected candidate genes (5-HTT, NPSR1,
COMT, MAOA, CRHR1, RGS2). Along with pharmacogenetics of SSRIs and SNRIs (5-HTT,
5-HT2A, COMT, CRHR1). SSRIs and SNRIs are the most commonly prescribed anxiety
medications. The authors indicate that SSRI escitalopram and SNRIs venlafaxine and duloxetine
have been the most researched for potential genetic markers to predict treatment response and
potential side effects. Since GAD is considered to have an inheritable genetic component,
knowing familial medication history could help eliminate medications for subsequent family
members diagnosed with GAD (Gottschalk and Domschke, 2017). GAD, which could provide,
initial relief of symptoms and better healthcare management.
The authors of this review point out the difficulties future trials must face with so many
different phenotypic variations. The study also only discussed three medications as first-line
therapies: escitalopram, venlafaxine, and duloxetine. With several medication possibilities, this
only looks at a small sample as potential genetic markers to predict treatment response or side
effects.
Cost Comparison in First-line Methods Versus Pharmacogenomic Testing
Individual response to therapeutics in managing anxiety varies widely, making treatment
options challenging (Najafzaheh et al., 2017). IDgenetix® is a pharmacogenomic test that has
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been shown to predict the response of medications based on an individual’s genetic makeup.
This study compared IDgenetix® versus treatment as usual groups. Quality adjusted life-years
were 2.09 and 1.94 for IDgenetix® patients versus 0.15 for treatment as usual (Najafzaheh et al.,
2017). Overall cost indicates a $535 cost saving for the IDgenetix® group (Najafzaheh et al.,
2017). Those patients who have severe HAM-A scores are hard to treat, require longer trial-anderror periods, causing increased clinical and economical costs (Najafzaheh et al., 2017).
This study concludes that IDgenetix® testing improves quality-adjusted life-years and
decreases overall costs over a three-year period (Najafzaheh et al., 2017). Limitations of this trial
include: the study only looked at those who have moderate to severe anxiety, leaving those with
only mild anxiety out of the trial, those with several comorbidities were excluded, and the study
did no further investigation after a three-year trial, therefore long-term progression is limited.
Brown et al. (2017) looked at a one-year trial to determine cost savings of
pharmacogenomic testing in patients with mental illness. The selected patients are being treated
by primary care providers or psychiatrists. A total of 2,168 patients underwent pharmacogenomic
testing and pharmacy records were obtained six months prior to the trial and one year after
testing (Brown et al., 2017). It concluded that those who received pharmacogenomic testing
saved $3,988 within that testing year (Brown et al., 2017). This study was an extension of a
previous study analyzing cost savings in pharmacogenomic testing; the original study suggests
patients save $1,036 in yearly medical costs (Brown et al., 2017).
While this study did provide positive information regarding pharmacogenomic testing, it
is not useful for this topic as it looked at the effects pharmacogenomics has on major depressive
disorder and not anxiety. However, it gives one an idea of the cost savings pharmacogenomic
testing can provide for many health conditions. Since depression and anxiety have such a strong
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medication correlation, and depression is usually the focus when the two coexist, it is beneficial
to understand result of all pharmacogenomic testing. Another limitation is the lack of therapeutic
outcome information, thus failing to clarify if cost savings and medication response are directly
related. This analysis did not take total health care costs into consideration but rather just looked
at medication costs.
Antidepressants are one of the top most commonly prescribed medications, but only
35%-45% of patients receive remission following initial therapy (Winner, Allen, Altar, &
Spahic-Mihajlovic, 2013). With such a high initial failure rate, this leads to a direct correlation
with treatment costs, disability claims, decreased productivity, and missed work. This one-year
blinded study evaluated eight direct or indirect health care utilizations and 96 patients were
diagnosed with depression or anxiety based on the DSM-IV-text revision (TR) criteria. The
Union Health Services (UHS) concluded this study, which primarily consisted of employed
adults of a heterogenous ethnic mix; those who had previous pharmacogenomic testing were
excluded from this study (Winner et al., 2013).
A buccal DNA swab was collected on each patient, thus measuring 50 alleles for the
following six genes cytochrome P450 genes: (CYP2D6, CYP2C19, CYP2C9, and CYP1A2),
serotonin transporter gene (SLC6A4), and serotonin 2A receptor gene (5HTR2A) (Winner et al.,
2013). These results were converted to a composite phenotype for each psychiatric medication
using the GeneSight report. Based on the pharmacogenomic tests, 26 medications were used in
the trial populations which were separated into red bin (use with caution and with more frequent
monitoring), yellow bin (use with caution), and green bin (use as directed) (Winner et al., 2013).
Of the trail participants nine (9%) fell into red bin population, 48 (50%) as yellow bin, and 39
(41%) green bin (Winner et al., 2013). Results concluded red bin individuals had 69% more
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health care visits (21.9) in comparison to green bin (13.7) and yellow bin (12.3) (p=0.014)
(Winner et al., 2013). Red bin participants also had 67% more general medical visits (12.8), in
comparison to green (8.4) bin and yellow (7.1) bin (p=0.039), along with more sick days, and
more disability claims, red (0.56) bin, green (0.15) bin, and yellow bin (0.11) bin, (p=0.013)
(Winner et al., 2013). Psychiatric visits also increased with red bin patients (8.9), in comparison
to green (5.1; p=0.057) bin or yellow (5; p=0.066) bin (Winner et al., 2013).
The authors of this study concluded that pharmacogenomic testing can help identify
appropriate and inappropriate medications, which in the long run can lead to decreased direct and
indirect healthcare utilization and cost (Winner et al., 2013). The red bin population was
associated with a higher number of psychiatric medications, which is linked indicating a
limitation. Another limitation noted, the study was based from a small sample population, and all
patients were under one psychiatrists care. Billing and reimbursement data were not readily
available from the study site but rather collected from available sources (Winner et al., 2013).
In reviewing literature, it was mentioned several times that many individuals fail first-line
anxiety treatment. Studies show that pharmacogenomic testing, which is based on an individual’s
genetic make-up, is yielding promising results in managing anxiety upon initial presentation.
Along with benefits associated with initial symptom management, improvement in overall
healthcare efficacy is increased, and overall cost of healthcare is decreased.
Discussion
Anxiety can be a difficult diagnosis as it typically presents with another medical problem,
depression being the most common dual diagnosis. Both anxiety and depression are managed
with SSRIs and SNRIs, with depression management taking precedence (Lee, 2018). Many of
the studies look at patients with both depression and anxiety, thus, limiting research on anxiety
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management alone. With limited research on independent anxiety management and
pathophysiology remaining multifactorial and not fully understood, research suggests
pharmacogenomic testing may help providers understand how anxiety medications are oxidized
in each individual patient. Gottschalk and Domschke (2017) researched the genetic inheritability
of GAD. Highlighting the significance in knowing familial medication history to help eliminate
potential first-line medications that will not work for subsequent family members (Gottschalk
and Domschke, 2017).
Pharmacogenomic testing is still being heavily researched and Maron and Nutt (2017),
indicate further research is needed for this testing to become standard of care. Current tests may
limit certain genetic race-ethnicity variants when selecting an appropriate genetic panel (Maron
and Nutt, 2017). Brown et al. (2017) provided significant cost saving numbers after their trial
patients depression were treated based on pharmacogenomic testing. While this study did not
focus on anxiety, it provides significant insight to the benefits of pharmacogenomic testing.
According to Drozda et al. (2015), “Published guidelines and updates to the United States
product labeling represent significant advances to our ability to implement pharmacogenomic
testing into clinical practice and how to use some this information when it is available” (p. 176).
However, information is still lacking in whether testing should be completed for gene variants
that influence drug metabolism (Drozda, et al., 2015). The lack of data provides a barrier for
patients to have the test covered by their insurance providers (Drozda et al., 2015). With
continued research and data collecting, insurance companies may find that a pharmacogenomic
testing will provide great insight in decreasing healthcare costs and increasing healthcare
efficacy.
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In treating anxiety, do those who elect to have pharmacogenomic testing versus those who
are treated based on first-line treatments have better symptom management?
Whether it is medication, CBT, or a combination of both, current literature suggests that
many patients fail first-line methods in treating anxiety. According to Crists-Christoph et al.
(2012), combination therapy provided no additional benefits and patients often refused CBT
when given the opportunity. Boland et al. (2018), concluded in their study only 50.6% of patient
remained on first-line provider preference medication, after pharmacogenetic testing was
completed. Thus, only 50% of patients are being managed effectively after initial first-line
treatment (Boland et al., 2018). However, Boland et al. (2018), explains that genetic variation
plays a major role in how medications are metabolized in the body. With genetic variations such
as SLC6A4 and MTHFR genotype, without pharmacogenetic testing, these patients would fail
several medication trials as these genes do not metabolize traditional first-line SSRI and SNRI
medications (Boland et al, 2018).
Bradley et al. (2018), also showed promising statistical benefits of pharmacogenetic
testing. Patients classified to have moderate to severe anxiety showed a reduction in anxiety
symptoms when they were prescribed medications based off NeuroIdgenetix® guided treatment.
The study also concluded that providers made less changes to medications to those who had the
genetic testing done in comparison to those who were prescribed provider preference
medications (Bradley et al., 2018).
In managing anxiety, would patients who respond to pharmacogenomic testing have
decreased healthcare costs and improve overall healthcare efficacy in comparison to those
who trial several medications?
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In comparing healthcare costs of first-line methods versus results from pharmacogenetic
testing, studies indicate decreased health care costs for those who receive pharmacogenetic
testing. Those who were part of the CALM trial saw an increase in healthcare costs of $245 over
an 18-month period (Joesch et al., 2013). These patients received medications based off first-line
medication treatment and were offered CBT. While those who had IDgenetix® pharmacogenetic
testing saw a decrease of $535 in healthcare costs over a three-year period (Najafzaheh et al.,
2017). When comparing these two studies, one must look at the trial length of each. With the
CALM study being conducted over 18-months and IDgenetix® over 36 months, the healthcare
costs of the CALM study would increase to $490 over a 3-year period. Statistically combining
these results, a CALM participant electing to have treatment based off pharmacogenetic testing
would save a total of $1,023 in healthcare costs over a three-year period.
Winner et al. (2013) also supports decreased healthcare costs for those who are treated
based on pharmacogenetic testing. Those who received medication labeled “use with caution and
frequent monitoring” saw a significant increase in treatment costs, more general medical visits,
more psychiatric visits, increase in disability claims, decreased productivity, and missed work
(Winner et al., 2013). Those who were treated with “use with caution” or “use as directed”
medications equally both saw decreased healthcare costs and increased healthcare efficacy with
decreased medical and psychiatric visits. (Winner et al., 2013). This trial was significant in
providing insight on providers who use previous experience or preference when prescribing
medications. While a medication may have worked on one or several patients prior, does not
mean it will work on all subsequent patients. By eliminating the trial and error method, patients
would be prescribed the most effective medication given how their bodies metabolize anxiety
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medications, which in the long run can lead to decreased direct and indirect healthcare utilization
and cost (Winner et al., 2013).
Applicability to Clinical Practice
Anxiety offers a wide range of symptoms and affects millions of people worldwide. No
matter what specialty one plans to practice or currently practices, every provider will come
across a patient with anxiety. Knowing the symptoms can help get an individual effective and
prompt treatment. Selecting medications based on genetic makeup will help guide the best
treatment option versus provider preference. Genetic testing will help providers understand why
a medication may or may not work for each patient. If a provider can treat anxiety symptoms on
initial primary care visit, this will lead to lower healthcare costs, and improve overall healthcare
efficacy.
Understanding how genetic testing works and implicating those results into practice is
promising for future medicine. Mills, Voora, Payser, & Haga (2013) discuss the current
limitations pharmacogenetic testing has in a primary care setting. Since this is a relatively new
therapeutic option, providers are not familiar with the test’s interpretation (Mills et al., 2013).
Therefore, providers are not offering this option to their patients. Integrating pharmacogenetic
testing into primary care is the most critical specialty as that is where most medications are
prescribed. The authors suggest providers become familiar with pharmacogenetic testing and
discuss with their patients the purpose of the testing, the roles genes play in medication
metabolism, risks versus benefits, limitations, alternatives, discuss procedure with the patient as
it involves a DNA analysis, and the future benefits the test may provide in future medication use
(Mills et al., 2013). As a provider, knowing how a medication will metabolize will also allow for
a warning to patients of certain side effects
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With more research, it appears pharmacogenetic testing could be standard of care as a
screening tool not only for anxiety medications but for several other health conditions. Once a
patient is tested, clinicians will know how several different classes of medications work based on
an individual’s genetic makeup. Thus, reducing the trial and error method of medication
management, decreasing healthcare costs, and increasing healthcare efficacy.
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